01—Abstract
Summary
Summary of the 8-K filed September 1, 2026. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals Incorporated announced a significant leadership transition in its finance department with the appointment of Jonathan Poole as Executive Vice President and Chief Financial Officer (CFO), effective January 1, 2027.
Mr. Poole, a seasoned finance executive with prior CFO experience at Evelo Biosciences and Genocea Biosciences, and extensive background at Shire plc, will succeed Charles F. Wagner, Jr. Mr. Wagner will transition from his CFO responsibilities to focus solely on his role as Executive Vice President and Chief Operating Officer. This appointment brings a well-qualified executive into a critical financial leadership position within Vertex.
Investors should note the details of Mr. Poole's compensation package, which includes a $750,000a base salary and a 90% target annual bonus. The agreements also outline severance provisions for termination without cause or resignation for good reason, including salary continuation and accelerated equity vesting, as well as change of control provisions designed to retain key talent during potential acquisition scenarios.
02—Key points
Key Highlights
- Jonathan Poole appointed as Executive Vice President and Chief Financial Officer (CFO), effective January 1, 2027.
- Charles F. Wagner, Jr. will remain as Executive Vice President and Chief Operating Officer, relinquishing CFO duties.
- Mr. Poole brings substantial financial leadership experience, including previous CFO roles and senior positions at Shire plc.
- Poole's base salary will be $750,000 with a target annual bonus of 90% of base salary.
- Employment agreement includes severance provisions for termination without cause or resignation for good reason.
- Change of control agreement provides enhanced severance and benefits upon specific termination events around a change of control.
- Mr. Poole's experience includes board positions at Acadia Pharmaceuticals Inc. and Codiak Biosciences, Inc.
03—Questions
Frequently Asked Questions
What is the primary reason for this filing?
This filing announces the appointment of Jonathan Poole as the new Chief Financial Officer (CFO) of Vertex Pharmaceuticals, effective January 1, 2027, and outlines the transition of CFO responsibilities from Charles F. Wagner, Jr.
What are the key terms of Jonathan Poole's employment agreement?
Mr. Poole will receive a base salary of $750,000 and a target annual bonus of 90% of his base salary. The agreement also details severance benefits in the event of termination without cause or resignation for good reason.
What is the significance of the change of control agreement?
The change of control agreement is designed to provide financial security and incentivize Mr. Poole to remain with the company during periods of potential corporate transition, such as a merger or acquisition. It offers enhanced severance and benefits if his employment is terminated without cause or if he resigns for good reason within a specified timeframe around a change of control.
Will Charles F. Wagner, Jr. be leaving Vertex Pharmaceuticals?
No, Charles F. Wagner, Jr. will continue with Vertex Pharmaceuticals. He will transition from his role as Chief Financial Officer to focus solely on his responsibilities as Executive Vice President and Chief Operating Officer.
04—Continue